RecruitingPhase 1NCT07413666
A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years
A Safety, Tolerability, Pharmacokinetic, Food Effect, and Proof-of-Concept Study of Single and Multiple Doses of ORX489 in Healthy Adults
Sponsor
Centessa Pharmaceuticals (UK) Limited
Enrollment
212 participants
Start Date
Feb 25, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
Characterize the safety, tolerability and pharmacokinetics of ORX489 following single and multiple doses.
Eligibility
Min Age: 18 YearsMax Age: 60 Years
Inclusion Criteria2
- Healthy males or females as determined by assessments at the Screening Visit.
- For Parts A, B, C, and D: Participants must be at least 18 years of age and no more than 60 years of age at the Screening
Exclusion Criteria3
- Presence of significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological, or psychiatric disease, as determined by medical history, physical examination, and screening investigations.
- History of seizure disorder, any other condition that increases the risk of seizure
- Has a clinically significant sleep disorder, including insomnia or sleep apnea
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGORX489 Tablets
ORX489 Tablets
OTHERPlacebo Tablets
Placebo Tablets
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07413666
Related Trials
Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt and Evaluation of Potential Drug-Drug Interactions
NCT072511531 location
A Comparative Bioavailability Study of Two Torasemide 10 mg Tablets Formulations in Healthy Adult Participants Under Fasting Conditions:
NCT072015841 location
Evaluating a Mat-Based Biometric Vibration System for Sleep and Daily Recovery
NCT072213181 location
Safety and Pharmacokinetics of Y-4 Tablets in Healthy Subjects
NCT069356821 location